18 Seiden MV,Swenerton KD,Matulonis U,etal A phase Ⅱ study of the MDR inhibitor biricodar(INCEL,VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy[J].Gynecol Oncol.2002 Sep;86(3):302-10.
19 Caponigro F, Basile M, de Rosa V, Normanno N.New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004[J].Anticancer Drugs. 2005 Feb;16(2):211-21.
20 Smith-Jones PM, Pandit-Taskar N,et al.Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003.[J]. Nucl Med Biol. 2008 Apr;35(3):343-51.
21 Wagner U,du Bois A,Pfisterer J,et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-aphase Ⅱ trial of the AGO Overian Cancer Study Group (AGO-OVAR 2.6) [J].Gynecol Oncol. 2007 Apr;105(1):132-7.Epub 2006 Dec 11.
22 Vasey PA, Gore M, Wilson R,et al. A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers[J].Br J Cancer. 2008 Jun 3;98(11):1774-80. Epub 2008 May 27.
23 Schilder RJ, Pathak HB, Lokshin AE,et al.Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash[J]. Gynecol Oncol. 2009 Jan 20. [Epub ahead of print].
24 Konner J, Schilder RJ, DeRosa FA,et al.A phase II study of cetuximab /paclitaxel /carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer [J].Gynecol Oncol. 2008 Aug;110(2):140-5. Epub 2008 Jun 13.
25 Dal Lago L, D'Hondt V, Awada A.Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors[J].Oncologist. 2008 Aug;13(8):845-58. Epub 2008 Aug 11.
26 Tew WP,Colombo N,et al.VEGF-Trap for patients with recurrent platinum-resistant epithelial ovarian cancer:preliminary results of a randomized,multicentre phaseⅡstudy[J].Proc Am Soc Clin Oncol.2007,25 (18s):5508a.
27 Lhommé C,Joly F,Nicoletto M,et al.Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer[J].J Clin Oncol. 2008 Jun 1;26(16):2674-82.
28 Mathew P,Fidler IJ,Logothetis CJ,et al.Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer[J].Semin Oncol. 2004 Apr;31(2 Suppl 6):24-9.
29 Matei D, Emerson RE,Schilder J,et al.Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial[J].Cancer. 2008 Aug 15;113(4):723-32.
30 Berek JS,Schultes BC,Nicodemus CF.Biologic and immunologic therapies for ovarian cancer[J].J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s.
31 Berek JS, Taylor PT, et al.CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer[J]. J Immunother. 2008 Feb-Mar;31(2):207-14.
32 Hirte H,Vergote IB,Jeffrey JR,et al.A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study[J].Gynecol Oncol.2006 Aug;102(2):300-8. Epub 2006 Jan 25.
33 Luo LY,Bunting P,Scorilas,et al.Human kallikrein 10: a novel tumor marker for ovarian carcinoma?[J].Clin Chim Acta, 2001 Apr;306(1-2):111-8.
34 Luo LY，Katsaros D，Scoril
